Related Experiment Videos
[Treatment of benign prostatic hyperplasia]
R Harzmann1, D Weckermann, F Wawroschek
1Urologische Klinik, Zentralklinikum Augsburg.
Zeitschrift Fur Arztliche Fortbildung Und Qualitatssicherung
|August 14, 1998
Summary
Benign prostatic hyperplasia (BPH) management has diversified with new drugs and procedures. Guidelines and the International Prostate Symptoms Score (IPSS) aid individualized, cost-effective BPH therapy.
Area of Science:
- Urology
- Pharmacology
- Medical Technology
Context:
- Benign prostatic hyperplasia (BPH) management has significantly diversified over the past decade.
- Traditional treatments like transurethral resection of the prostate (TURP) face alternatives.
- An aging population and financial constraints necessitate updated therapeutic strategies.
Purpose:
- To outline the evolving landscape of BPH diagnosis and treatment.
- To highlight the importance of individualized therapy in the context of BPH.
- To emphasize the role of new pharmacological agents, endoscopic interventions, and diagnostic tools.
Summary:
- Pharmacological options, including alpha receptor blockers and DHT-synthesis inhibitors, are increasingly important alongside phytotherapeutics.
- Instrumental methods offer alternatives to traditional surgical procedures for BPH.
- Development of diagnostic guidelines and the International Prostate Symptoms Score (IPSS) is crucial for effective and accessible BPH management.
Impact:
- Facilitates the development of individualized BPH therapy plans.
- Aims to enhance treatment efficacy and patient outcomes.
- Addresses financial barriers by promoting cost-effective therapeutic approaches.